Savara Inc. (the “Company”) (Nasdaq: SVRA ), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced additional analyses from its pivotal Phase 3 IMPALA-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback